Annexon Q1 FY26 net loss narrows to $44.1 million

Annexon, Inc.

Annexon, Inc.

ANNX

0.00
  • Annexon posted a net loss attributable to common stockholders of USD 44.1 million, or USD 0.23 per share, for first-quarter 2026, narrowing from a loss of USD 54.4 million, or USD 0.37 per share, a year earlier.
  • Research and development expense fell to USD 35.8 million from USD 48.2 million, while general and administrative costs rose to USD 10.3 million from USD 9.2 million.
  • Cash, cash equivalents, short-term investments totaled about USD 225 million as of March 31, 2026; operating runway expected into second-half 2027.
  • Topline Phase 3 ARCHER II data for vonaprument in geographic atrophy expected in Q4 2026, with BLA submission for tanruprubart in Guillain-Barré syndrome anticipated in 2026 on initial U.S./European FORWARD data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071601PRIMZONEFULLFEED9715805) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.